Latest News

A statistically significant OS benefit was observed with relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.

The 48-month OS rate was 78.6% with pembrolizumab vs 60.4% with placebo among patients with advanced or recurrent endometrial cancer.

Belantamab mafodotin plus triplet induction and maintenance yields responses in transplant-ineligible newly diagnosed multiple myeloma population.

Data from the phase 1/1b CHRYSALIS-2 trial show enduring responses with amivantamab plus lazertinib in this EGFR-mutated NSCLC population.

Delaying cytoreductive surgery until after 6 cycles of neoadjuvant chemotherapy did not improve DFS vs interval surgery after 3 cycles in patients with advanced high-grade epithelial ovarian cancer.

The objective response rate was significantly higher with sac-TMT plus pembrolizumab vs pembrolizumab alone in the phase 3 OptiTROP-Lung05 trial.

Long-term follow-up from the phase 3 RUBY trial revealed a 54% estimated cure rate with the dostarlimab combination in dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Data from the phase 2 ERASMM trial support further evaluation of elranatamab among patients with high-risk smoldering multiple myeloma.

Saum Ghodoussipour, MD, suggested that advances in liquid biopsy tracking, next-generation ADCs, and organ-sparing approaches may be featured at ASCO 2026.

Nathan Goodyear, MD, MDH, broke down how findings from the CHALLENGE and OPTIMUS studies show that structured exercise may turn cold tumors hot.

Matthew Matasar, MD, of Rutgers Cancer Institute, spoke about upcoming trials in lymphoma to look out for at the ASCO 2026 Meeting.

Community-clinic data shows real-world EFS and pCR closely match KEYNOTE-522, strengthening confidence in real-world endpoints for eTNBC care.

Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life.

Presentations at the 2026 ASCO Annual Meeting may reveal key advances in the use of different bispecific antibodies and CELMoDs in multiple myeloma care.

Nathan Goodyear, MD, explained why exercise must be treated as a precise, prescribable therapy in oncology to combat AEs and improve long-term survival.

Although colorectal cancer is not on the plenary stage at the 2026 ASCO Annual Meeting, there are still lots of high-profile trials reporting data.

Data from the phase 3 POTOMAC trial supported the FDA approval of durvalumab plus BCG in this non-muscle invasive bladder cancer population.

Enrollment for the WATER IV study evaluating aquablation vs radical prostatectomy has concluded, with primary end point results planned by spring 2027.

Sonikpreet Aulakh, MBBS, MD, discussed the shift toward multiomic personalization and tumor microenvironment reprogramming in neuro-oncology.

The FDA has assigned a Prescription Drug User Fee Act date of November 27, 2026, for neladalkib in this ALK-positive non–small cell lung cancer population.

Explore key insights on operationalizing bispecific antibodies in community oncology, outpatient step-up dosing, and shared staffing infrastructure.

The FDA extends camizestrant review. Plus, promising Bria-IMT survival data and a ctDNA blood test that spots breast cancer recurrence 4 years early.

Data from the phase 1/2 CADENZA trial support the approval of pivekimab sunirine for patients with blastic plasmacytoid dendritic cell neoplasms.

Orelabrutinib is now available in Australia for patients with relapsed/refractory mantle cell lymphoma.

The European Medicine Agency’s CHMP has adopted a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in this treatment-naïve mCRC population.

Developers intend to submit a supplemental new drug application for toripalimab/chemotherapy in resectable stage II or III NSCLC.

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.

Host Brandon Mancini, MD, MBA, FACRO, discusses stereotactic radiosurgery, proton therapy, and other relevant modalities in the management of brain tumors.